MedTrace Logo

Early Recanalization After Intravenous Thrombolysis With Tenecteplase Versus Alteplase in Distal Vessel Occlusion Strokes

NCT05635786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 319

Last updated 2025-03-13

No results posted yet for this study

Summary

The purpose of this monocentric retrospective study is to compare, in patients with acute distal vessel occlusion stroke, the early rates of successful recanalization in patients treated with Alteplase (ALT) versus Tenecteplase (TNK), based on a retrospective analysis of magnetic resonance imaging (MRI) performed early after IVT.

Conditions

  • Acute Distal Vessel Occlusion Stroke

Interventions

DRUG

Alteplase (0.9mg/kg)

Intravenous thrombolysis with Alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.

DRUG

Tenecteplase (0.25mg/kg)

Intravenous thrombolysis with Tenecteplase (0.25mg/kg, maximum 25 mg) with 100% of the dose given as a bolus.

Sponsors & Collaborators

  • Centre Hospitalier Sud Francilien

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-02
Primary Completion
2024-11-21
Completion
2024-11-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05635786 on ClinicalTrials.gov